Targeted treatments and immunotherapy for non-small cell lung cancer
Event date and time: 10 December 2024, 9:30 am to 12:30 pm
Who should attend:
This course is ideal for research nurses, clinical nurse specialists, pharmacists and clinical trials coordinators. It may also be of interest to other healthcare professionals involved in the diagnosis and treatment of people with non-small cell lung cancer such as junior doctors.
How to register:
Click here to register.
There is a fee of £150.00 (covering both sessions)
Delivered over two morning sessions, Dr Elaine Vickers – a leading independent educator on the science of new cancer treatments – will guide you through many of the most relevant topics relating to modern systemic treatments for non-small cell lung cancer (NSCLC).
The first session will focus on the gene faults that drive many NSCLCs and on the targeted treatments that exploit these faults, such as inhibitors of EGFR, ALK, ROS1, B-Raf, HER2, MET and RET.
The second explores cancer’s relationship with the immune system and on the checkpoint inhibitor group of immunotherapies, which include PD-1, PD-L1 and CTLA-4 targeted antibody therapies.